• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Pharmacokinetics,distribution,and excretion of sodium oligomannate,a recently approved anti-Alzheimer's disease drug in China

    2022-04-07 12:46:50JiaojiaoLuQiongqunPanJieqiangZhouYanWengKailiChenLvShiGuanxiuZhuChunlinChenLiangLiMeiyuGengZhenqingZhang
    Journal of Pharmaceutical Analysis 2022年1期

    Jiaojiao Lu,Qiongqun Pan,Jieqiang Zhou,Yan Weng,Kaili Chen,Lv Shi,Guanxiu Zhu,Chunlin Chen,Liang Li,*,Meiyu Geng,Zhenqing Zhang

    aJiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases;College of Pharmaceutical Sciences,Soochow University,Suzhou,Jiangsu,215021,China

    bShanghai Green Valley Pharma.Corp.,Shanghai,201203,China

    cMedicilon Preclinical Research(Shanghai)LLC,Shanghai,201299,China

    dState Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai,201203,China

    Keywords:

    Sodium oligomannate

    Alzheimer's disease

    Pharmacokinetics

    LC-MS/MS

    Oligosaccharide

    A B S T R A C T

    The National Medical Products Administration has authorized sodium oligomannate for treating mild-tomoderate Alzheimer's disease.In this study,an LC-MS/MS method was developed and validated to quantitate sodium oligomannate in different biomatrices.The plasma pharmacokinetics,tissue distribution,and excretion of sodium oligomannate in Sprague-Dawley rats and beagle dogs were systematically investigated.Despite its complicated structural composition,the absorption,distribution,metabolism,and excretion profiles of the oligosaccharides in sodium oligomannate of different sizes and terminal derivatives were indiscriminate.Sodium oligomannate mainly crossed the gastrointestinal epithelium through paracellular transport following oral administration,with very low oral bioavailability in rats(0.6%-1.6%)and dogs(4.5%-9.3%).Absorbed sodium oligomannate mainly resided in circulating body fluids in free form with minimal distribution into erythrocytes and major tissues.Sodium oligomannate could penetrate the blood-cerebrospinal fluid(CSF)barrier of rats,showing a constant area under the concentration-time curve ratio(CSF/plasma)of approximately 5%.The cumulative urinary excretion of sodium oligomannate was commensurate with its oral bioavailability,supporting that excretion was predominantly renal,whereas no obvious biliary secretion was observed following a single oral dose to bile duct-cannulated rats.Moreover,only 33.7%(male)and 26.3%(female)of the oral dose were recovered in the rat excreta within 96 h following a single oral administration,suggesting that the intestinal flora may have ingested a portion of unabsorbed sodium oligomannate as a nutrient.

    1.Introduction

    Sodium oligomannate was found to be safe and effective for treating mild-to-moderate Alzheimer's disease(AD)in clinical phase II and phase III studies[1,2].It was authorized by the National Medical Products Administration(NMPA)of China in November 2019 and became available to the Chinese market in December 2019[3,4].It is the only drug approved worldwide in almost 17 years to treat mild-to-moderate AD[5].This approval is great news to patients,family members,and doctors.

    Sodium oligomannate is derived from alginate via two chemical modification steps[6].Alginate is a linear polysaccharide extracted from brown seaweeds and is composed of β-D-mannuronic acid(M)and α-L-guluronic acid(G)with an exclusive 1→4 linkage[7,8].Homogenous polymannuronic acid(M block),polyguluronic acid(G block)domains,and heterogeneous polymanuronic/polyguluronic acid domain(M/G block)occur in alginate[9,10].Partial hydrolysis breaks the M/G block and releases M and G blocks.Subsequently,sodium oligomannate was produced from the purified M block with oxidative degradation.Sodium oligomannate is characterized as β-1-4-linked oligomannuronic acid with certain molecular weight distribution(degree of polymerization from 2 to 10)and a series of mannuronic acid-derived polyhydroxy dicarboxylic acid residues at the reducing terminal of each sugar chain(Fig.1).

    Fig.1.Representative chemical structure of sodium oligomannate(dp:degree of polymerization;n=2 to 10).

    Recently,sodium oligomannate was reported to treat mild-tomoderate AD by indirectly regulating gut microbiota,that is,the gut-brain axis mechanism[11].Sodium oligomannate can directly inhibit amyloid-β fibril formation[12,13].As a drug with a novel mechanism for treating neurodegenerative diseases,with potentially new neuro-clinical indications[11]but a complicated structural composition,it is important to verify whether sodium oligomannate enters the systemic circulation and then the brain after oral administration.However,it is crucial to clarify the mechanism of sodium oligomannate.Few methods have been developed and validated for analyzing sodium oligomannate directly in a biological matrix with high accuracy,sensitivity,specificity,and efficiency,as it has an intrinsically complex structure,such as a relatively high molecular weight(670-880 Da),high polarity(carbohydrate-based structure),and complicated composition(size normally distributed and sugar chain terminal derivatives randomly distributed).Thus,the absorption,distribution,metabolism,and excretion(ADME)study of sodium oligomannate lags behind other pharmaceutical studies and clinical studies.

    Several methods have been considered to determine sodium oligomannate concentrations in biometrics.However,most of these methods have proven inadequate.The specificity of antibody assays is affected by endogenous glycans,such as heparin,hyaluronic acid,heparan sulfate,dermatan sulfate,and N/O-glycans[14-16].Biofunctional assays are limited by the problems of amyloid-β-related stability and operability[17,18].Moreover,none of the bioassays can effectively discriminate sugar chains of different sizes in biological samples[19-21].Due to its low sample volume requirements,high selectivity,and high sensitivity,LC-MS/MS has become the preferred method for ADME studies[22-24].A few LCMS/MS methods have been reported for the quantitation of oligosaccharides in biological samples,but chemical or enzymatic degradation and post-degradation derivatization before analysis are generally required[25,26].

    Here,we developed an LC-MS/MS method to quantify sodium oligomannate directly in different animal biomatrices,including rat plasma,urine,cerebrospinal fluid(CSF),feces,bile,tissues,and dog plasma.Based on this method,we are trying to answer several important questions:1)whether,how,and how much sodium oligomannate enters the systemic circulation and CSF following oral administration;2)whether the ADME behaviors of oligosaccharides with different sizes of sodium oligomannate are the same;and 3)whether sodium oligomannate is metabolized in vivo?The results will help us understand the anti-Alzheimer mechanism of sodium oligomannate and deepen our understanding of its efficacy and safety in clinical use.

    2.Materials and methods

    2.1.Chemicals and reagents

    Sodium oligomannate was provided by Shanghai Green Valley Pharmaceutical Co.,Ltd.(Shanghai,China).The internal standard(IS)d8-valine was purchased from Sigma-Aldrich(St.Louis,MO,USA).All reagents and solvents were of HPLC or analytical grade and were obtained from reliable commercial sources.

    2.2.Animals

    Sprague-Dawley(SD)rats(SPF grade,180-240 g,6-8 weeks)were purchased from Sino-British SIPPR/BK Lab Animal Ltd.(Shanghai,China)and kept under a 12 h light/dark cycle in a temperature-controlled(25°C)room.SPF rodent growth and reproduction feed and reverse osmosis(RO)purified water were provided ad libitum.All beagle dogs(5.7-10.6 kg)were purchased from Beijing Marshall Biotechnology Co.,Ltd.(Beijing,China).The dog maintenance feed and RO purified water were provided ad libitum.

    2.3.Oligosaccharide profile of sodium oligomannate

    2.3.1.Preparation of standard samples using blank matrices for oligosaccharide profiling

    Stock solutions of sodium oligomannate were prepared in ultrapure water.A series of standard working solutions were prepared by diluting the stock solution with water.The standard working solution(2 μL)was added to 38 μL of the blank matrix(plasma,urine,CSF,or fecal homogenate),and the mixture was vortexed for 1 min to generate the standard samples.It is well known that the concentration of an analyte affects greatly the accuracy of mass spectral detection,and a wide range of sodium oligomannate concentrations in biological matrices after oral or intravenous administration can also be expected.Under these circumstances,the concentration range of the prepared standard samples was roughly equivalent to the expected actual concentration range of sodium oligomannate in the corresponding biological matrices.

    2.3.2.Drug administration for oligosaccharide profiling

    An appropriate amount of sodium oligomannurate was weighed,added to the required amount of sterile water for injection,vortexed,and sonicated to obtain a colorless or light-yellow transparent solution.Following a single oral administration of sodium oligomannate at different dosages to SD rats or beagle dogs,blood,urine,and feces samples were collected individually predose and at given time points.Immediately after the collection of blood samples into EDTA-K2tubes,plasma was collected by centrifugation.All samples were stored at-70°C prior to the analysis.Details of the drug dosage,collected substrates,and sampling time points are presented in Table 1.

    Table 1Animals,dosage,matrix,and sampling time points after oral administration.

    2.3.3.Sample preparation

    Protein precipitation methods were used to extract sodium oligomannates from biological samples.For each plasma or CSF sample(50 μL),250 μL of extraction solvent(ethanol:acetonitrile:water=34:51:15,containing 50μg/mL d8-valine as an IS)was added.The mixture was vortexed for 2 min and then centrifuged at 18,000 r/min for 7 min.The supernatant was then ready for LC-MS/MS analysis.For rat urine and bile samples,equal volumes of rat plasma were added,and the mixed samples were processed using the same procedure as that used for the plasma sample.Feces and tissue samples were homogenized with ultrapure water at a volume:weight ratio of 10 mL/g.A total of 100μL blank plasma(500 μL)and extraction solvent were added to 100 μL of homogenate,vortexed for 2 min,and then centrifuged at 18,000 r/min for 7 min.The supernatant was analyzed using LC-MS/MS.

    2.3.4.LC-MS/MS conditions

    The accurate mass and characteristic fragment ions of each component in sodium oligomannate were confirmed using an HILIC-UPLC-Orbitrap MS/MS system(data not shown).Based on these results,the characteristic ion pairs(precursor ion→product ion)of each sodium oligomannate component were selected to construct the multiple reaction monitoring(MRM)ion reaction in LC-MS/MS analysis,and the MS conditions of each ion reaction were optimized to improve the detection sensitivity.

    The analyte and IS were separated using a Waters Atlantis?T3(150 mm ×2.1 mm I.D.,3μm)column on a Waters Acquity UPLC system(Milford,MA,USA).The mobile phase was 10 mM ammonium formate in water(mobile phase A)and acetonitrile(mobile phase B),with gradients programmed as follows:initial 5%B maintained for 1.4 min,which was increased to 95%B after 0.4 min,maintained for 1.2 min,then decreased to 5%B in 0.1 min,and maintained for 1.4 min.The flow rate was 0.25 mL/min.An SCIEX Triple Quad?6500 tandem mass spectrometer(Concord,Canada)with an electrospray ionization source was used in the negative mode for mass detection.The MS parameters were as follows:ion spray voltage,-4,500 V;ion source temperature,500°C;curtain gas,35 a.u.;nebulizing gas(GS1),50 a.u.;auxiliary gas(GS2),50 a.u.;and declustering potential,80 V.The collision energy was optimized for each tested sugar chain.

    2.3.5.Sodium oligomannate oligosaccharide profiling in biosamples

    Because of the interference of endogenous substances in biological matrices,particularly due to their low content and poor ionization efficiency,components with a large degree of polymerization(dp;6 to 10)cannot be accurately determined using the above-mentioned LC-MS/MS method.However,the oligosaccharides of dp2-dp5 are major components of the drug according to their specifications(approximately 85%)based on refractive index detection.Thus,in this study,the smaller-sized components(dp2 to dp5)of sodium oligomannate were used to construct the oligosaccharide profile to understand whether oligosaccharides with different sizes behave indiscriminately.The MRM transitions of these components are listed in Table 2.

    Table 2The formula,characteristic ions,and collision energy(CE)of each oligosaccharide in sodium oligomannate.

    The peak area of each oligosaccharide detected in the MRM mode in LC-MS/MS was integrated.The relative percentage based on the peak area of each oligosaccharide component in a sample was calculated by dividing the peak area by the sum of the peak areas of all components.Consequently,an oligosaccharide profile of sodium oligomannate was constructed.

    2.4.Method validation

    Based on the results obtained from the oligosaccharide profiling studies,a representative component,dp2-2(m/z 355.0→193.0),was selected as the MS detection indicator of sodium oligomannate to develop a bioanalytical method with d8-valine as the IS(m/z 124.0→45.0).Subsequently,the established LC-MS/MS method for absolute quantification of sodium oligomannate concentrations in biological samples was fully validated in accordance with the United States Food and Drug Administration(FDA)Guidance for Industry for Bioanalytical Method Validation,which included system suitability,selectivity,linearity,carryover,accuracy and precision,dilution,recovery,matrix effect,and stability.

    2.5.Pharmacokinetic studies in rats

    Fifty SD rats were randomly assigned to five groups consisting of equal numbers of male and female rats(n=10 in each group).The animals were fasted overnight prior to drug administration and until 4 h after administration.Rats from group 1 received an intravenous bolus injection of sodium oligomannate at a 2 mg/kg dosage.Serial blood samples(pre-dose,0.083,0.25,0.5,0.75,1,1.5,2,4,8,and 24 h)were collected from the jugular vein into EDTA-K2tubes.Rats from groups 2-4 received gavage doses of 100,200,and 400 mg/kg.Serial blood samples(pre-dose,0.167,0.33,0.5,1,2,4,6,8,10,and 24 h)were collected.For rats from group 5,multiple gavage doses of sodium oligomannate at 200 mg/kg/day were administered for 8 days before serial blood samplings(pre-dose on days 4,5,6,7,and 8,and 0.167,0.33,0.5,1,2,4,6,8,10,and 24 h post-dose on day 8)were collected.Plasma was collected by centrifuging the blood at 3,000 g for 5 min and stored at-70°C until analysis.

    Pharmacokinetic parameters,including area under the plasma concentration versus time curve(AUC),plasma clearance(CLP),elimination half-life(t1/2),mean residence time(MRT),and volume of distribution(Vz),were calculated via a non-compartmental method using the Phoenix WinNonlin 7.0 software(Certara,Princeton,NJ,USA).

    2.6.Tissue distribution studies in rats

    Twenty-four SD rats were randomly assigned to three groups(n=8 per group)with equal numbers of male and female rats.The animals were fasted overnight prior to drug administration 4 h later.Following oral administration of 400 mg/kg of sodium oligomannate,blood samples were collected from the cardiac punctures at 0.25(group 1),1(group 2),and 6 h(group 3),and plasma was collected by centrifuging the blood at 3,000 g for 5 min.After blood sample collection,representative tissues or organs,including the brain,heart,lung,liver,stomach,spleen,kidney,skeletal muscle,abdominal fat,testis(ovary),uterus,bladder,small intestine,and large intestine,were dissected,washed with saline solution,weighed,dried,and stored at-70°C until analysis.

    2.7.Plasma protein binding

    The in vitro binding of sodium oligomannate to rat and beagle dog plasma proteins was determined at concentrations of 1,10,and 100 μM.Plasma samples containing sodium oligomannate(100μL)were subjected to equilibrium dialysis(n=3)against an equal volume of phosphate-buffered saline(PBS,pH 7.4)at 37°C with gentle shaking at 60 r/min.After 5 h of equilibration,samples were drawn from the buffer chambers,and the plasma chambers were added with the same volume of plasma or PBS to achieve the same conditions.The mixtures were then diluted with 85% aqueous ethanol containing 10μg/mL IS,and the supernatant was analyzed by LCMS/MS.

    The concentration of the compound was expressed as the peak area ratio(peak area sodium oligomannate/peak area internal standard),and the protein binding rate was calculated according to the following formula:

    2.8.Blood-brain barrier permeability in rats

    A total of 150 male SD rats were randomly assigned to three groups(n=50 in each group).Animals from each group were then divided into ten subgroups according to time points(n=5 for each time group).Animals were fasted overnight prior to drug administration and received an intravenous bolus injection of sodium oligomannate at doses of 20,40,and 60 mg/kg.Blood samples were collected from the jugular vein into EDTA-K2tubes at predetermined time points(pre-dose,0.083,0.25,0.5,1,2,4,8,10,and 24 h).Plasma was collected by centrifuging the blood at 3,000 g for 5 min.CSF was collected by direct needle puncture in rats while they were anesthetized.All samples were stored at-70°C until further analysis.

    2.9.Excretion studies in rats

    Sixteen SD rats were randomly assigned to two groups(n=8 in each group)with equal numbers of male and female rats.The animals were fasted overnight prior to drug administration 4 h later.Rats from group 1 were placed separately in metabolism cages and orally administered 400 mg/kg of sodium oligomannate after an overnight fast.Urine and feces were collected during periods of 0-4,4-8,8-24,24-48,48-72,and 72-96 h after administration.Rats from group 2 were anesthetized,and bile ducts were inserted before oral administration of sodium oligomannate(400 mg/kg).Bile was collected during periods of 0-4,4-8,8-24,and 24-48 h post-dose.All samples were stored at-70°C until further analysis.

    2.10.Pharmacokinetic experiments in beagle dogs

    Twenty-four beagle dogs were randomly assigned to four groups(n=6 in each group)with equal numbers of males and females and housed individually in stainless steel mobile cages.The animals were fasted overnight prior to drug administration and until 4 h later.Dogs from group 1 received an intravenous bolus injection of sodium oligomannate at a dose of 1 mg/kg.Serial blood samples(pre-dose,0.083,0.25,0.5,1,2,3,4,6,8,and 24 h)were collected from the jugular vein into EDTA-K2--containing tubes.Dogs from groups 2 and 4 received gavage doses of 50 and 200 mg/kg,respectively.Serial blood samples(pre-dose,0.25,0.5,1,2,4,6,8,10,and 24 h)were collected.For dogs in group 3,multiple gavage doses of sodium oligomannate at 100 mg/kg/day were administered for 7 days,followed by the collection of serial blood samples(pre-dose,0.25,0.5,1,2,4,6,8,10,and 24 h at both day 1 and day 7,and pre-dose at days 4,5,and 6)were collected.Plasma was collected by centrifuging the blood at 2,200 g for 10 min and stored at-70°C until analysis.

    3.Results

    3.1.The oligosaccharide profile of sodium oligomannate

    3.1.1.The rat plasma oligosaccharide profile

    The mass spectral peak area of each of the 12 sodium oligomannate components was proportional to the concentration of sodium oligomannate in standard samples prepared with blank rat plasma at concentrations ranging from 200 to 30,000 ng/mL.The linear calibration curves are shown in Fig.2A,and regression equations and correlation coefficients(r2)are listed in Table S1.The disaccharide component dp2-2 showed the highest response,followed by dp2-1 and two trisaccharide components,dp3-1 and dp3-2.

    Fig.2.Linear calibration curves for each sodium oligomannate component in(A)rat plasma,(C)urine,(E)feces,and(G)cerebrospinal fluid(CSF)and the oligosaccharide profiles of sodium oligomannate in(B)rat plasma,(D)urine,(F)feces,and(H)CSF.

    The oligosaccharide profiles of sodium oligomannate in standard rat plasma samples and rat plasma collected at different time points following oral gavage of 3,000 mg/kg sodium oligomannate were obtained,as shown in Fig.2B.Similar oligosaccharide profiles observed in both the real plasma samples and the standard sample(spike-in)demonstrated the indiscriminate absorption of sodium oligomannate components to systematic circulation in rats following oral gavage.In addition,oligosaccharide profiles of sodium oligomannate did not change significantly with pharmacokinetic sampling time,indicating that the clearance of sodium oligomannate from the systemic circulation was also indiscriminate.

    3.1.2.The rat urine oligosaccharide profile

    The mass spectral peak area of each of the 12 sodium oligomannate components was proportional to the concentration of sodium oligomannate in standard samples prepared with blank rat urine at concentrations ranging from 1,000 to 200,000 ng/mL.The linear calibration curves are shown in Fig.2C,and the regression equations and correlation coefficients(r2)are listed in Table S1.The disaccharide component dp2-2 showed the highest response,followed by dp3-1,dp2-1,and dp3-2.The oligosaccharide profiles of sodium oligomannate in standard rat urine samples and in rat urine collected at different time points following oral gavage of 1,000 mg/kg sodium oligomannate are shown in Fig.2D.Similar oligosaccharide profiles were observed in both the real urine samples and the spiked urine sample.The fact that oligosaccharide profiles did not change significantly with the sampling periods strongly suggests the indiscriminate elimination of sodium oligomannate components from rat kidneys.

    3.1.3.The rat feces oligosaccharide profile

    The mass spectral peak areas of each of the twelve sodium oligomannate components were proportional to the concentration of sodium oligomannate in the standard samples prepared with blank rat fecal homogenate at concentrations ranging from 100 to 1,800μg/mL.The linear calibration curves are shown in Fig.2E,and regression equations and correlation coefficients(r2)are listed in Table S1.The disaccharide component dp2-2 showed the highest response,followed by dp2-1,dp3-1,and dp3-2.The oligosaccharide profiles of sodium oligomannate in standard rat feces samples and rat feces collected at different periods following oral gavage of 1,000 mg/kg sodium oligomannate are shown in Fig.2F.Similar oligosaccharide profiles were observed in both real fecal samples and the spike-in feces sample.The fact that oligosaccharide profiles did not change significantly with the sampling periods strongly suggests indiscriminate elimination of sodium oligomannate components from the rat intestine.

    3.1.4.The rat CSF oligosaccharide profile

    The mass spectral peak areas of each of the seven sodium oligomannate components were proportional to the concentration of sodium oligomannate in the standard samples prepared with blank rat CSF at concentrations ranging from 50 to 5,000 ng/mL.The linear calibration curves are shown in Fig.2G,and regression equations and correlation coefficients(r2)are listed in Table S1.The disaccharide components dp2-2 and dp2-1 showed relatively high responses.The oligosaccharide profiles of sodium oligomannate in the standard rat CSF sample and rat CSF collected at different periods following intravenous injection of 40 mg/kg sodium oligomannate are shown in Fig.2H.Similar oligosaccharide profiles were observed in both the real CSF samples and the spiked CSF sample.The fact that oligosaccharide profiles did not change significantly with the sampling time strongly suggests the indiscriminate distribution of sodium oligomannate components in rat CSF.

    3.1.5.The dog plasma oligosaccharide profile

    To verify whether there was any difference between species,the oligosaccharide profile in dog plasma was also investigated.Similar to the observations in rats,similar oligosaccharide profiles observed in both the real plasma samples and the spike-in plasma sample demonstrated the indiscriminate absorption and clearance of sodium oligomannate components in dogs following oral gavage 300 mg/kg sodium oligomannate.Detailed data are shown in the supplementary data(Fig.S1).

    3.2.LC-MS/MS method validation

    The highly similar oligosaccharide profiles observed in the prepared samples and the actual biological samples after drug administration suggest that each of these components can be used as an indicator of sodium oligomannate in mass spectral detection.To obtain a higher detection sensitivity,a representative disaccharide component of sodium oligomannate,dp2-2 (m/z 355.0→193.0),was used to develop a bioanalytical method with d8-valine as the IS(m/z 124.0→45.0).Calibration curves for sodium oligomannate were fitted via linear weighted(1/x2)leastsquares regression.

    The established LC-MS/MS method for absolute quantification of sodium oligomannate concentration was fully validated in rat plasma,urine,liver homogenate,and dog plasma,and partially validated in rat blood,fecal homogenate,bile,and tissue homogenate(other than liver),according to the Guidance for Industry for Bioanalytical Method Validation issued by both the United States FDA and the NMPA of China.The results of full validation in rat plasma,urine,liver homogenate,and dog plasma,including system suitability,selectivity,linearity,carryover,accuracy and precision,dilution, recovery, matrix effect, stability and typical chromatograms,are shown in Supplementary data,Tables S2-S5,and Figs.S2-S5.The validated linear ranges of sodium oligomannate concentrations in the biological matrices are shown in Table 3.

    Table 3The calibration ranges of sodium oligomannate concentrations in biological matrices.

    3.3.Pharmacokinetic of sodium oligomannate in SD rats

    Concentrations of sodium oligomannate in rat plasma were quantified using a fully validated LC-MS/MS method.The mean plasma concentration versus time profiles for sodium oligomannate in male and female rats are shown in Figs.3A-C,and the main pharmacokinetic parameters are presented in Table 4.

    Table 4Pharmacokinetic parameters of sodium oligomannate in Sprague-Dawley rats.

    Following single intravenous administration of 2 mg/kg sodium oligomannate,AUC(0-t)for male and female rats were 2.49 and 2.04h·μg/mL,respectively.Vzvalues were relatively small(546mL/kg for males and494mL/kg for females)compared with 670mL/kg of the total body water in rats,indicating minimal extravascular distribution.Circulating sodium oligomannate underwent rapid clearance as indicated by the short terminal t1/2values(0.49h in males and 0.36h in females).In accordance,the drug exhibited high blood clearance of 2319 and 2885 mL/h/kg(obtained by dividing CLPby the blood/plasma ratio of 0.33)inmale and female rats,which are comparable to the rat renal blood flow(2200 mL/h/kg).

    Following a single oral administration of 100,200,or 400 mg/kg sodium oligomannate,the increase in mean maximum plasma concentrations(Cmax)for male(1:1.5:3.1)and female(1:1.6:2.1)rats,as well as for plasma exposure(AUC(0-t))in female rats(1:1.3:2.5)were less than dose-proportional,whereas the increase in AUC(0-t)in male rats(1:2.5:5.9)was slightly higher than doseproportional(Fig.3D).The time to maximum concentration(tmax)in male and female rats was 0.6-2.47 h and 0.4-3.77 h,respectively.MRT was 1.93-3.82 h and 2.99-4.16 h,respectively,in males and females.The oral bioavailability of sodium oligomannate in rats was determined to be 0.1%-1.6%.

    Fig.3.The mean plasma concentration-time profiles of sodium oligomannate in rats(A)after a single 2.0 mg/kg intravenous administration;(B)after single or multiple oral doses in males;(C)after single or multiple oral doses in females;(D)exposure-dose relationship after single oral doses of 100,200,and 400 mg/kg.

    After repeated oral doses of sodium oligomannate(200 mg/kg)to SD rats for 8 days,there was no significant difference in the plasma concentration values before the fourth,fifth,sixth,seventh,and eighth dosing(roughly around the LLOQ,0.100μg/mL),indicating that the plasma exposure to sodium oligomannate reached a steady state.After multiple doses,the tmaxand MRT values did not change significantly compared with those from a single dose.The Cmaxratios(RCmax)of the last dose to the first dose for male and female rats were 4.1 and 1.6,and the AUC0-tratios(RAUC)were 2.2(males)and 1.6(females),respectively,indicating that there was a certain accumulation in SD rats following a repeated oral dose.

    3.4.Tissue distribution of sodium oligomannate in SD rats

    Sodium oligomannate concentrations in male and female rat tissue samples collected at 0.25,1,and 6 h after oral administration of 400 mg/kg are presented in Fig.4.It was mainly distributed in the gastrointestinal tract,while the concentrations in other organs and tissues were low.At 0.25 h after administration,higher drug concentrations were observed in the small intestine and stomach,whereas the small intestine and large intestine were the principal organs of sodium oligomannate distribution at 1 h and 6 h postdose,respectively.

    Fig.4.The concentration of sodium oligomannate in(A)male and(B)female rat tissues at 0.25,1,and 6 h after a single 400 mg/kg oral dose.

    3.5.Plasma protein binding of sodium oligomannate

    The in vitro binding of sodium oligomannate to rat and beagle dog plasma proteins was determined by equilibrium dialysis.The results showed that the binding rate of the drug to rat and dog plasma proteins was less than 7.4% and virtually 0,respectively,in the concentration range of 1-100μM.

    3.6.Blood-brain barrier permeability of sodium oligomannate in SD rats

    To investigate whether sodium oligomannate could penetrate the blood-brain barrier to reach the brain,male SD rats were administered three doses by intravenous injection.Serial blood and CSF samples were collected,and LC-MS/MS quantified the concentrations of sodium oligomannate.The mean plasma and CSF concentration versus time profiles for sodium oligomannate are shown in Figs.5A and B,respectively.Exposure of rat plasma and CSF to sodium oligomannate was dose-proportional(Fig.5C).

    Fig.5.Mean plasma concentration-time profiles of sodium oligomannate in(A)rat plasma and(B)CSF after single intravenous administration.(C)The exposure-dose relationship after single intravenous doses of 20,40,and 60 mg/kg.

    Following a single intravenous injection of 20 and 40 mg/kg to SD rats,sodium oligomannate was detected in the CSF as early as 5 min after the dose.The mean peak CSF concentrations were 454.4 and 1215.4 ng/mL,with a tmaxof 0.5 h.Following a single 60 mg/kg intravenous injection of sodium oligomannate,peak CSF concentration(1406.4 ng/mL)was observed at the first sampling time point(5 min).Plasma/CSF exposure(AUCPlasma/AUCCSF)of sodium oligomannate at 20,40,and 60 mg doses were 31,912/1420,63,744/3209,85,757/4334 h·ng/mL,respectively.The mean bioavailability(obtained by dividing AUCCSFby AUCPlasma)of sodium oligomannate to rat CSF was 4.45%,5.03%,and 5.05%,respectively.

    3.7.Excretion of sodium oligomannate in SD rats

    Both intact and bile duct-cannulated(BDC)rats were used to determine the excretion routes of sodium oligomannate following an oral dose of 400 mg/kg.Concentrations of sodium oligomannate in rat urine,feces,and bile were measured by LC-MS/MS analysis.The cumulative excretion amounts in rat urine,feces,and bile were calculated,and the cumulative excretion percentage curves are shown in Fig.6.At 96 h post-dosing,35.2%(1.2% in urine,0.3% in wash solution,and 33.7% in feces)and 27.1%(0.8% in urine,0.1% in wash solution,and 26.3% in feces)of sodium oligomannate were excreted into male and female rat urine and feces,respectively.Bile excretion in male and female bile duct-cannulated rats accounted for less than 0.004% of the dose within 48 h after administration.

    Fig.6.Cumulative excretion curves of sodium oligomannate after a single 400 mg/kg oral dose to SD rats,(A)in 0-96 h urine;(B)in 0-96 h feces;(C)total recovery in urine and feces after 0-96 h.

    3.8.Pharmacokinetics of sodium oligomannate in beagle dogs

    Concentrations of sodium oligomannate in dog plasma were quantified using a fully validated LC-MS/MS method.The mean plasma concentration versus time profiles for sodium oligomannate in male and female dogs are shown in Figs.7A-C,and the main pharmacokinetic parameters are presented in Table S6.Following single intravenous administration of 1 mg/kg sodium oligomannate,the AUC(0-t)for male and female dogs was 2.95 and 3.31 h·μg/mL,respectively.The Vzvalues(380 mL/kg for males and 360 mL/kg for females)were roughly comparable to the extracellular fluid in dogs(280 mL/kg)and much less than the total body water in dogs(600 mL/kg),indicating minimal extravascular distribution in dogs.Rapid clearance of sodium oligomannate from circulation was revealed by the short terminal t1/2in male(0.81 h)and female dogs(0.86 h).The CLp of sodium oligomannate in male and female dogs were determined to be 321 and 290 mL/h/kg,respectively,and due to the lack of the blood/plasma ratio,its blood clearance in dogs was not determined.

    After a single oral administration of 50,100,and 200 mg/kg sodium oligomannate,the increases in Cmaxand AUC(0-t)for male(1:1.1:1.8 for Cmaxand 1:1.1:1.9 for AUC)and female(1:1.2:1.7 for Cmaxand 1:1.3:2.4 for AUC)dogs were less than dose-proportional(Fig.7D).The tmaxand MRT values in male and female dogs were 0.7-1.7 h and 3.4-6.2 h,respectively.The oral bioavailability of sodium oligomannate in dogs was determined to be 4.2%-9.3%.

    Fig.7.Mean plasma concentration-time profiles of sodium oligomannate in dogs(A)after a single 1.0 mg/kg intravenous administration;(B)after single or multiple oral doses in males;(C)after single or multiple oral doses in females;(D)exposure-dose relationship after single oral doses of 50,100 and 200 mg/kg.

    Following repeated oral doses of sodium oligomannate(100 mg/kg)for 7 days,there was no significant difference in the plasma concentration values before the fourth,fifth,sixth,and seventh dosing in male dogs(roughly around the LLOQ,0.100μg/mL),whereas the trough concentration increased slightly in female dogs over time(0.15,0.25,0.23,and 0.31μg/mL before the fourth,fifth,sixth,and seventh dosing).Compared to the first dose,tmaxand MRT after multiple doses did not change significantly.RCmaxof the last dose to the first dose for male and female dogs was 0.8 and 1.2,and the RAUCvalues for male and female dogs were 1.0 and 1.2,respectively,indicating no accumulation in dogs following a repeated oral sodium oligomannate dose.

    4.Discussion

    Sodium oligomannate,a newly authorized drug for the improvement of cognitive function in patients with mild-to-moderate AD,was found to reduce gut microbiota dysbiosis-promoted neuroinflammation and amyloid β plaque deposition in AD progression[11-13].Due to the oligosaccharide nature of sodium oligomannate,it has long been debated whether this substance can be absorbed effectively and cross the blood-brain barrier into the central nervous system(CNS)after oral administration.It seems that it is not an ideal lead compound for CNS drugs from the perspective of traditional pharmaceutical chemists[27],such as complicated composition,relatively large molecular weight,high polarity,too many hydrogen bond donors and receptors,and strong dissociation tendency under physiological conditions(acidic pKa 3.59).

    Elucidating the ADME properties of a drug in the body is an important prerequisite for understanding drug efficacy and safety[28].However,the lack of a reliable biological method impeded the ADME evaluation of sodium oligomannate due to its complicated composition and disadvantageous physicochemical properties in view of instrument detection.

    As sodium oligomannate comprises a series of oligosaccharides with different sizes and terminal derivatives,they were profiled in various biosamples to verify if they behave differently in ADME.The comprehensive results showed no significant difference in the oligosaccharide profiles between the spiked samples and corresponding real rat plasma,urine,feces,CSF,and dog plasma samples collected over the pharmacokinetic sampling time post-dose.This finding suggests the indiscriminate absorption,distribution,and excretion of the oligosaccharides from sodium oligomannates with different sizes and terminal derivatives and no apparent intertransformation between these components.

    An LC-MS/MS method to quantify sodium oligomannate in various bio-matrixes was developed,validated,and applied based on oligosaccharide profiling.The ADME properties of sodium oligomannate in animals were investigated.

    The oral bioavailability of sodium oligomannate in rats(0.1%-1.6%)and dogs(4.2%-9.3%)was very low.In addition,sodium oligomannate showed extremely low membrane permeability(Papp<1×10-7cm/s in the concentration range of 75-300μM)in the Caco-2 cell monolayer model(data not shown).It did not act as a substrate for uptake transporters,including the organic anion transporting polypeptide 1B1(OATP1B1),OATP1B3,organic anion transporter 1(OAT1),OAT3,and organic cation transporter 2,and efflux transporters,including P-glycoprotein and breast cancer resistant protein(data not shown).Since sodium oligomannate is primarily ionized at physiological pH(7.4)due to its low acidic pKa value,it may cross the epithelium through paracellular transport[29,30].It is further postulated that rats are a better model than dogs(which tend to produce overestimations)for predicting human oral bioavailability of paracellularly absorbed compounds due to species-dependent physiological differences[31,32].Thus,the oral bioavailability of sodium oligomannate in humans is expected to be low.

    After absorption into the systemic circulation,sodium oligomannate is likely to remain in circulating body fluids with minimal extravascular distribution to most organs and tissues regardless of blood flow or blood volume,as indicated by its small Vzvalues in both rats and dogs.Circulating sodium oligomannate does not bind to albumin and mainly exists in the free form.Its distribution into erythrocytes was minimal,as indicated by its low blood/plasma ratio(0.33)in SD rats.High concentrations of sodium oligomannate were only found in the digestive tract-related organs in a timedependent gastrointestinal transport manner after a single oral dose of 400 mg in SD rats.Sodium oligomannate can quickly penetrate the blood-CSF barrier following intravenous injection,as indicated by the short tmaxvalues observed in the CSF sample(less than 0.5 h).In addition,the dose-dependent increase in sodium oligomannate exposure in both CSF(AUCCSF)and plasma(AUCPlasma)resulted in a constant AUC ratio of approximately 5%,indicating that the distribution of sodium oligomannate from the circulation to the CSF solely depends on the concentration gradient between them.In contrast,the Cmaxvalue in rat CSF increased slightly higher than the dose increases between the dose range of 20 mg/kg and 40 mg/kg,while there was no significant change at a higher dose,such as 60 mg/kg.Collectively,these data suggest a paracellular transport mechanism of sodium oligomannate that penetrates the blood-CSF barrier in SD rats[33,34].

    After a single oral administration to BDC rats,virtually no detectable sodium oligomannate was observed in the bile samples up to 48 h post-dose,indicating a minor role of biliary excretion during elimination.The cumulative urinary excretion(1.5% for males and 0.9% for females)of sodium oligomannate is equivalent to its oral bioavailability(1.3% for men and 1.0% for women),supporting a predominantly renal sodium oligomannate excretion.Considering that the oligosaccharide profiles remained the same and no significant difference was observed between bioavailability and urine excretion ratio,no metabolism was suggested.Moreover,the rapid clearance of sodium oligomannate by the rat(blood clearance comparable to the renal blood flow)and dog(CLPequal to 22%-25% of the renal blood flow)kidney resulted in a short terminal t1/2in rats(less than 0.5 h)and dogs(0.8 h)following intravenous administration.

    Interestingly,only 33.7% and 26.3% of the oral dose was recovered in male and female rats within 96 h following a single oral dose,respectively.Two factors may have contributed to this phenomenon.First,the unabsorbed sodium oligomannate in the feces sample was not fully extracted by our procedure,and second,a portion of unabsorbed sodium oligomannate was ingested by the intestinal flora as a nutrient,or both.

    In conclusion,the ADME profiles of a newly approved innovative anti-AD drug,sodium oligomannate,were investigated.The results showed that it could be absorbed into the systemic circulation after oral administration with low bioavailability.Sodium oligomannate was also detected in the CSF of rats but at a very low level.The absorbed portion was neither metabolized by the body nor distributed extensively to the tissues but was quickly excreted into the urine.The intestinal flora may ingest part of the unabsorbed drug as a nutrient,and the remaining portion is excreted with feces.

    CRediT author statement

    Jiaojiao Lu:Methodology,Investigation,Writing-Original draft preparation;Qiongqun Pan:Methodology,Investigation,Writing-Original draft preparation;Jieqiang Zhou:Methodology;Yan Weng:Data curation,Validation;Kaili Chen:Data curation,Validation;Lv Shi:Methodology;Guanxiu Zhu:Project administration, Data curation, Validation; Chunlin Chen: Project administration;Liang Li:Methodology,Investigation,Writing-Original draft preparation;Meiyu Geng:Conceptualization,Supervision,Writing-Reviewing and Editing;Zhenqing Zhang:Conceptualization,Supervision,Writing-Reviewing and Editing,Funding acquisition.

    Declaration of competing interest

    The authors declare that there are no conflicts of interest.

    Acknowledgments

    This work was supported by the National Natural Science Foundation of China(Grant No.:81673388),the Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases(Grant No.:BM2013003),and the Priority Academic Program Development of Jiangsu Higher Education Institutes(PAPD).

    Appendix A.Supplementary data

    Supplementary data to this article can be found online at https://doi.org/10.1016/j.jpha.2021.06.001.

    精品少妇久久久久久888优播| 久久99一区二区三区| 精品人妻一区二区三区麻豆| 97人妻天天添夜夜摸| 久久影院123| 久9热在线精品视频| 亚洲欧美一区二区三区黑人| 宅男免费午夜| 免费一级毛片在线播放高清视频 | 国产黄色免费在线视频| 欧美激情 高清一区二区三区| 黑人巨大精品欧美一区二区蜜桃| 不卡av一区二区三区| 久久久久久久精品精品| 亚洲国产欧美在线一区| 国产精品成人在线| 女人久久www免费人成看片| 亚洲第一av免费看| 在线观看www视频免费| 欧美日韩国产mv在线观看视频| 久久ye,这里只有精品| 久久久精品国产亚洲av高清涩受| 亚洲欧美一区二区三区黑人| 99国产精品免费福利视频| tube8黄色片| 麻豆乱淫一区二区| 精品卡一卡二卡四卡免费| 欧美少妇被猛烈插入视频| 欧美黄色淫秽网站| 午夜福利在线免费观看网站| 精品亚洲成国产av| 国产精品一二三区在线看| 在线观看舔阴道视频| 伦理电影免费视频| 成人黄色视频免费在线看| 日韩视频一区二区在线观看| 亚洲精品一二三| av天堂在线播放| 国产视频一区二区在线看| 亚洲av片天天在线观看| av天堂久久9| 亚洲av男天堂| 亚洲激情五月婷婷啪啪| 91成年电影在线观看| 久久av网站| 国产精品久久久人人做人人爽| 亚洲av成人不卡在线观看播放网 | 热99久久久久精品小说推荐| 十八禁高潮呻吟视频| 日韩一区二区三区影片| 国产1区2区3区精品| 国产国语露脸激情在线看| 狠狠狠狠99中文字幕| 亚洲成av片中文字幕在线观看| 丝袜喷水一区| 麻豆乱淫一区二区| 免费在线观看视频国产中文字幕亚洲 | 香蕉国产在线看| 日本a在线网址| videosex国产| 亚洲国产精品999| 日韩电影二区| 精品人妻1区二区| 蜜桃国产av成人99| 国产成人一区二区三区免费视频网站| 另类亚洲欧美激情| av在线app专区| 亚洲国产欧美日韩在线播放| av免费在线观看网站| 搡老熟女国产l中国老女人| 成人18禁高潮啪啪吃奶动态图| 国产精品成人在线| 日韩三级视频一区二区三区| 久久精品熟女亚洲av麻豆精品| 妹子高潮喷水视频| 国产精品免费视频内射| 老司机在亚洲福利影院| 国产成人精品久久二区二区免费| 夫妻午夜视频| 色婷婷av一区二区三区视频| 久久香蕉激情| 免费高清在线观看视频在线观看| 亚洲精品中文字幕一二三四区 | 免费黄频网站在线观看国产| 老熟妇仑乱视频hdxx| 一级黄色大片毛片| 久久精品亚洲熟妇少妇任你| 99久久99久久久精品蜜桃| 精品国产乱子伦一区二区三区 | 亚洲精品在线美女| 亚洲午夜精品一区,二区,三区| 亚洲欧美一区二区三区久久| 国产激情久久老熟女| 免费看十八禁软件| 成人免费观看视频高清| av欧美777| 午夜免费成人在线视频| 老汉色∧v一级毛片| 性色av一级| 777久久人妻少妇嫩草av网站| 99九九在线精品视频| 国产av国产精品国产| 淫妇啪啪啪对白视频 | 亚洲色图综合在线观看| 久久综合国产亚洲精品| 一级毛片电影观看| √禁漫天堂资源中文www| 在线av久久热| 一区二区av电影网| 久久精品久久久久久噜噜老黄| 欧美日韩成人在线一区二区| 老鸭窝网址在线观看| 国产免费福利视频在线观看| 叶爱在线成人免费视频播放| 久久国产精品大桥未久av| 久久久水蜜桃国产精品网| 欧美黑人欧美精品刺激| 天堂俺去俺来也www色官网| 欧美性长视频在线观看| 精品国产国语对白av| 精品一区二区三区av网在线观看 | 国产伦理片在线播放av一区| 精品视频人人做人人爽| 丝袜喷水一区| 人人妻,人人澡人人爽秒播| 免费在线观看影片大全网站| 水蜜桃什么品种好| 欧美精品啪啪一区二区三区 | 午夜激情av网站| 超碰成人久久| av电影中文网址| 看免费av毛片| 国产成人av激情在线播放| 成人影院久久| 国产男女内射视频| 久久久久视频综合| 国产成人av教育| 久久香蕉激情| 亚洲成人久久爱视频| 亚洲精品久久国产高清桃花| 亚洲精品粉嫩美女一区| 五月玫瑰六月丁香| 久久精品夜夜夜夜夜久久蜜豆 | 久久99热这里只有精品18| 国产一区在线观看成人免费| 色在线成人网| 久久久国产欧美日韩av| 日韩欧美国产一区二区入口| 国产三级中文精品| 黄色 视频免费看| 色哟哟哟哟哟哟| 亚洲精品在线美女| 妹子高潮喷水视频| 亚洲在线自拍视频| 99热这里只有是精品50| 久久久久久久久免费视频了| 91大片在线观看| 精品久久久久久久久久免费视频| 两个人看的免费小视频| 夜夜躁狠狠躁天天躁| 国产精品一区二区免费欧美| 精品国产乱子伦一区二区三区| 午夜福利成人在线免费观看| 在线观看日韩欧美| 午夜激情福利司机影院| 免费在线观看成人毛片| 国产视频内射| 亚洲第一欧美日韩一区二区三区| 精品无人区乱码1区二区| 日本一区二区免费在线视频| 三级毛片av免费| 操出白浆在线播放| 麻豆国产av国片精品| 欧美人与性动交α欧美精品济南到| 在线观看午夜福利视频| 夜夜爽天天搞| 成人午夜高清在线视频| 中亚洲国语对白在线视频| 最近最新免费中文字幕在线| 中国美女看黄片| 青草久久国产| 欧美日韩福利视频一区二区| 日本撒尿小便嘘嘘汇集6| 老司机午夜十八禁免费视频| 精品一区二区三区四区五区乱码| 国内精品久久久久久久电影| 国产欧美日韩一区二区精品| 香蕉国产在线看| 久久久久国内视频| 亚洲七黄色美女视频| 免费搜索国产男女视频| 这个男人来自地球电影免费观看| 久久久久国内视频| 亚洲欧美日韩高清专用| 最新在线观看一区二区三区| 最新在线观看一区二区三区| 久久久久国产一级毛片高清牌| 精品欧美一区二区三区在线| x7x7x7水蜜桃| 精品欧美一区二区三区在线| 午夜成年电影在线免费观看| 在线播放国产精品三级| 国产人伦9x9x在线观看| 淫妇啪啪啪对白视频| 真人做人爱边吃奶动态| 国产亚洲精品av在线| 超碰成人久久| 小说图片视频综合网站| 黄色 视频免费看| www.自偷自拍.com| 亚洲成人中文字幕在线播放| 99久久精品热视频| 亚洲,欧美精品.| 国产av不卡久久| 欧美日韩中文字幕国产精品一区二区三区| 琪琪午夜伦伦电影理论片6080| 琪琪午夜伦伦电影理论片6080| 亚洲人成77777在线视频| 免费观看人在逋| cao死你这个sao货| 男人的好看免费观看在线视频 | 精品高清国产在线一区| 超碰成人久久| 一二三四在线观看免费中文在| 精品国产超薄肉色丝袜足j| 亚洲av成人不卡在线观看播放网| 亚洲自拍偷在线| 在线观看一区二区三区| 黄色视频不卡| 视频区欧美日本亚洲| 亚洲熟妇中文字幕五十中出| 91成年电影在线观看| 18禁美女被吸乳视频| 精品久久久久久久末码| 国产熟女午夜一区二区三区| av片东京热男人的天堂| 久久草成人影院| 国产片内射在线| 伦理电影免费视频| 国产成人av激情在线播放| 国产久久久一区二区三区| 国产97色在线日韩免费| 亚洲av电影不卡..在线观看| 成熟少妇高潮喷水视频| 国内久久婷婷六月综合欲色啪| 最近最新中文字幕大全电影3| 一级毛片精品| 白带黄色成豆腐渣| 熟女电影av网| 国内少妇人妻偷人精品xxx网站 | 777久久人妻少妇嫩草av网站| 麻豆成人av在线观看| 日本免费一区二区三区高清不卡| 亚洲欧美日韩无卡精品| 人人妻人人澡欧美一区二区| 国产一区在线观看成人免费| 床上黄色一级片| cao死你这个sao货| 无人区码免费观看不卡| 日本三级黄在线观看| 波多野结衣巨乳人妻| 久热爱精品视频在线9| 亚洲av成人不卡在线观看播放网| 久久婷婷人人爽人人干人人爱| av有码第一页| av超薄肉色丝袜交足视频| 首页视频小说图片口味搜索| 国产又黄又爽又无遮挡在线| 免费观看精品视频网站| 国产成+人综合+亚洲专区| 三级国产精品欧美在线观看 | 999精品在线视频| 久久精品夜夜夜夜夜久久蜜豆 | 91国产中文字幕| 又爽又黄无遮挡网站| 久久人妻av系列| 好看av亚洲va欧美ⅴa在| 亚洲国产高清在线一区二区三| 欧美日本亚洲视频在线播放| 99久久精品热视频| 亚洲无线在线观看| 1024视频免费在线观看| 老司机午夜十八禁免费视频| 高清在线国产一区| 精品高清国产在线一区| 小说图片视频综合网站| 男人舔奶头视频| 久久婷婷人人爽人人干人人爱| 亚洲精品美女久久av网站| 国产亚洲精品久久久久5区| 最近在线观看免费完整版| 在线观看日韩欧美| 女警被强在线播放| 欧美日韩亚洲国产一区二区在线观看| 亚洲天堂国产精品一区在线| 真人做人爱边吃奶动态| 国产精品98久久久久久宅男小说| 日本黄色视频三级网站网址| 成人国产一区最新在线观看| 久久精品夜夜夜夜夜久久蜜豆 | 国产精品av久久久久免费| 色精品久久人妻99蜜桃| 亚洲免费av在线视频| 精品国产乱子伦一区二区三区| 在线a可以看的网站| av中文乱码字幕在线| 欧美黑人欧美精品刺激| 两个人视频免费观看高清| 嫁个100分男人电影在线观看| 久久久久国产一级毛片高清牌| 可以在线观看毛片的网站| 国产精品一区二区三区四区免费观看 | cao死你这个sao货| 日本一区二区免费在线视频| 午夜成年电影在线免费观看| 中文资源天堂在线| 999精品在线视频| 国产精品一及| 亚洲欧美一区二区三区黑人| 国产真实乱freesex| 正在播放国产对白刺激| www日本在线高清视频| av中文乱码字幕在线| 久久精品国产亚洲av香蕉五月| 18禁国产床啪视频网站| 我要搜黄色片| 久久久精品国产亚洲av高清涩受| 国产又黄又爽又无遮挡在线| 亚洲午夜精品一区,二区,三区| 午夜福利高清视频| 美女午夜性视频免费| 少妇裸体淫交视频免费看高清 | 桃色一区二区三区在线观看| 国产99久久九九免费精品| 国产视频一区二区在线看| 亚洲成人免费电影在线观看| 无遮挡黄片免费观看| 久久精品影院6| 国产成人精品无人区| e午夜精品久久久久久久| 男女那种视频在线观看| 国产伦在线观看视频一区| 波多野结衣高清无吗| 麻豆国产97在线/欧美 | 精品久久久久久久久久久久久| 曰老女人黄片| 亚洲自拍偷在线| 亚洲无线在线观看| 亚洲成人久久爱视频| 最近最新中文字幕大全电影3| 国产视频一区二区在线看| 在线永久观看黄色视频| 夜夜爽天天搞| 日本在线视频免费播放| 国产黄片美女视频| 美女免费视频网站| av超薄肉色丝袜交足视频| www.www免费av| 久久伊人香网站| 婷婷亚洲欧美| av欧美777| 精品国产乱码久久久久久男人| 99精品久久久久人妻精品| 国产精品久久电影中文字幕| 黄色毛片三级朝国网站| 亚洲熟女毛片儿| 欧美日本亚洲视频在线播放| 久久久精品欧美日韩精品| 三级毛片av免费| 亚洲中文日韩欧美视频| 日韩精品青青久久久久久| 舔av片在线| bbb黄色大片| 中文字幕高清在线视频| 在线a可以看的网站| 精华霜和精华液先用哪个| 欧美日韩亚洲综合一区二区三区_| 97超级碰碰碰精品色视频在线观看| 欧美久久黑人一区二区| 欧美乱色亚洲激情| 亚洲美女黄片视频| 变态另类丝袜制服| 18禁黄网站禁片午夜丰满| 搡老熟女国产l中国老女人| 中文亚洲av片在线观看爽| 丰满人妻一区二区三区视频av | 亚洲第一欧美日韩一区二区三区| 两性午夜刺激爽爽歪歪视频在线观看 | 亚洲自偷自拍图片 自拍| 婷婷精品国产亚洲av| 色噜噜av男人的天堂激情| 最近最新免费中文字幕在线| 久久伊人香网站| 婷婷精品国产亚洲av| 久久精品国产清高在天天线| 丝袜人妻中文字幕| 国产激情久久老熟女| 亚洲一区中文字幕在线| 18禁国产床啪视频网站| tocl精华| 日韩精品中文字幕看吧| 日韩精品免费视频一区二区三区| 在线观看免费日韩欧美大片| 级片在线观看| 久久香蕉精品热| 一进一出好大好爽视频| 精品久久久久久久毛片微露脸| 久久久久国产一级毛片高清牌| 在线十欧美十亚洲十日本专区| 亚洲国产精品999在线| 一级片免费观看大全| 日本一本二区三区精品| 老熟妇仑乱视频hdxx| 天天添夜夜摸| 成人三级做爰电影| 日本成人三级电影网站| 18禁国产床啪视频网站| 欧美成狂野欧美在线观看| 国内精品久久久久精免费| 亚洲国产欧美网| 大型黄色视频在线免费观看| 免费观看人在逋| 老司机福利观看| 精品少妇一区二区三区视频日本电影| 中文字幕人妻丝袜一区二区| 国产熟女午夜一区二区三区| 久久久久免费精品人妻一区二区| 999久久久国产精品视频| 岛国视频午夜一区免费看| 成人手机av| 蜜桃久久精品国产亚洲av| 麻豆成人av在线观看| 天堂动漫精品| 一本久久中文字幕| 99热这里只有是精品50| 亚洲精品在线观看二区| 国产一区二区三区在线臀色熟女| 亚洲第一欧美日韩一区二区三区| 又紧又爽又黄一区二区| 波多野结衣高清作品| bbb黄色大片| 搞女人的毛片| 国产蜜桃级精品一区二区三区| 别揉我奶头~嗯~啊~动态视频| 欧美激情久久久久久爽电影| 女同久久另类99精品国产91| 久久香蕉国产精品| 美女 人体艺术 gogo| 国产精品一区二区三区四区免费观看 | 亚洲欧美日韩东京热| 99久久精品热视频| 在线观看日韩欧美| 又黄又爽又免费观看的视频| 五月玫瑰六月丁香| 国产亚洲欧美98| 精品不卡国产一区二区三区| 午夜福利免费观看在线| 国产v大片淫在线免费观看| 在线观看免费视频日本深夜| 琪琪午夜伦伦电影理论片6080| 熟女少妇亚洲综合色aaa.| 国产午夜福利久久久久久| 极品教师在线免费播放| 伦理电影免费视频| 精品人妻1区二区| 18美女黄网站色大片免费观看| 成人欧美大片| 中文字幕人成人乱码亚洲影| 好男人在线观看高清免费视频| 国产熟女xx| 久久天堂一区二区三区四区| 精品无人区乱码1区二区| 午夜激情av网站| 国产精品日韩av在线免费观看| 人妻久久中文字幕网| 岛国在线免费视频观看| 久久热在线av| 久久人人精品亚洲av| 男插女下体视频免费在线播放| 国产精品亚洲美女久久久| 欧美午夜高清在线| 久久久久性生活片| 在线观看免费视频日本深夜| 欧美性猛交黑人性爽| 高清在线国产一区| 99国产极品粉嫩在线观看| 99riav亚洲国产免费| 两性午夜刺激爽爽歪歪视频在线观看 | 亚洲精品美女久久久久99蜜臀| 热99re8久久精品国产| 国产视频一区二区在线看| 淫秽高清视频在线观看| 亚洲天堂国产精品一区在线| 一级a爱片免费观看的视频| 国产欧美日韩一区二区精品| 又黄又爽又免费观看的视频| videosex国产| 制服人妻中文乱码| 亚洲成人精品中文字幕电影| 久久香蕉激情| 国语自产精品视频在线第100页| a级毛片a级免费在线| 九色国产91popny在线| 日韩成人在线观看一区二区三区| 午夜福利视频1000在线观看| 亚洲欧美日韩东京热| 国产午夜精品久久久久久| 日本在线视频免费播放| 丁香欧美五月| 日本一区二区免费在线视频| 熟女电影av网| 狠狠狠狠99中文字幕| 看黄色毛片网站| 国产精品一区二区三区四区久久| 国产v大片淫在线免费观看| 91字幕亚洲| 亚洲色图 男人天堂 中文字幕| 激情在线观看视频在线高清| 免费看美女性在线毛片视频| 国产探花在线观看一区二区| 久久这里只有精品中国| 久久精品国产99精品国产亚洲性色| 人妻夜夜爽99麻豆av| 桃红色精品国产亚洲av| 岛国在线观看网站| 国内毛片毛片毛片毛片毛片| 国产精品电影一区二区三区| 在线免费观看的www视频| 亚洲第一电影网av| 草草在线视频免费看| 黄色丝袜av网址大全| 国产精品av视频在线免费观看| 欧美中文综合在线视频| 人人妻人人澡欧美一区二区| 久久久国产成人免费| 又紧又爽又黄一区二区| 亚洲国产精品成人综合色| 亚洲av五月六月丁香网| 中亚洲国语对白在线视频| 两性午夜刺激爽爽歪歪视频在线观看 | 18禁美女被吸乳视频| 亚洲中文日韩欧美视频| АⅤ资源中文在线天堂| 亚洲天堂国产精品一区在线| 国产一区在线观看成人免费| 老司机午夜福利在线观看视频| 神马国产精品三级电影在线观看 | 国语自产精品视频在线第100页| 久久中文字幕一级| 亚洲成av人片在线播放无| 黄色视频不卡| 啦啦啦韩国在线观看视频| 岛国视频午夜一区免费看| 亚洲欧洲精品一区二区精品久久久| 美女午夜性视频免费| 欧美丝袜亚洲另类 | 美女大奶头视频| 国产高清视频在线播放一区| 我的老师免费观看完整版| 少妇裸体淫交视频免费看高清 | 在线观看午夜福利视频| 国产aⅴ精品一区二区三区波| 在线永久观看黄色视频| 精品一区二区三区四区五区乱码| 欧美日韩黄片免| 91国产中文字幕| 日韩精品青青久久久久久| 午夜免费激情av| 午夜影院日韩av| 成年女人毛片免费观看观看9| 黄色女人牲交| 午夜久久久久精精品| 变态另类丝袜制服| 精品国内亚洲2022精品成人| 亚洲av熟女| 久久久久久九九精品二区国产 | 不卡av一区二区三区| а√天堂www在线а√下载| 欧美三级亚洲精品| 最近在线观看免费完整版| 精华霜和精华液先用哪个| 可以免费在线观看a视频的电影网站| 婷婷六月久久综合丁香| 亚洲欧洲精品一区二区精品久久久| 欧美一区二区国产精品久久精品 | 一区福利在线观看| 欧美日韩亚洲国产一区二区在线观看| 黄色视频不卡| 午夜激情av网站| 在线观看午夜福利视频| 日韩成人在线观看一区二区三区| 可以免费在线观看a视频的电影网站| 99在线人妻在线中文字幕| 亚洲中文日韩欧美视频| 男人的好看免费观看在线视频 | 麻豆av在线久日| 变态另类成人亚洲欧美熟女| 99久久国产精品久久久| 精品国产超薄肉色丝袜足j| 成年女人毛片免费观看观看9| 欧美+亚洲+日韩+国产| 亚洲欧洲精品一区二区精品久久久| 丝袜美腿诱惑在线| 国产伦一二天堂av在线观看| 久久午夜亚洲精品久久| 欧美一区二区精品小视频在线| 法律面前人人平等表现在哪些方面| 国产欧美日韩一区二区三| 一本综合久久免费| 亚洲七黄色美女视频| 久久久久久人人人人人| 国产精品永久免费网站| 亚洲男人天堂网一区| 欧美日韩瑟瑟在线播放| 日韩高清综合在线|